CD274 and non-small cell lung carcinoma: Given the response rates to anti-PD1/anti-PD-L1 therapies in other studies of patients with NSCLC, our expectation is that this approach will be effective in preventing metastatic progression for some, but not all early-stage NSCLC patients.